Is Artelo Biosciences going out of business?

ARTELO BIOSCIENCES, INC. (ARTL) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

ARTELO BIOSCIENCES, INC. (ARTL) scores 15 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 203.15% (YoY)

Five questions, kept separate

Survival - Critical

2-4 mo of estimated runway from 2026-06-30, based on $4.2M of cash and short-term investments against $15.9M of annual burn. Adjusted shares outstanding increased 203.2% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

14% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 203.15% (YoY)
• Debt / Equity: -0.83x (Net Cash)
• Interest coverage: -38.3x
• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -199.40%
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-27.

Price as of 2026-09-07.